Association between lipoprotein(a) and nonalcoholic fatty liver disease among Korean adults

Clinica Chimica Acta

Volumn 461, Issue , 2016, Pages 14-18

  Nam, Ji Sun ^a   Jo, Sehee ^a   Kang, Shinae ^a   Ahn, Chul Woo ^a   Kim, Kyung Rae ^a   Park, Jong Suk ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Insulin resistance; Lipoprotein(a); Nonalcoholic fatty liver disease

Indexed keywords

CHOLESTEROL; GLUCOSE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; LIPOPROTEIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTHROPOMETRIC PARAMETERS; ARTICLE; BIOCHEMICAL ANALYSIS; BLOOD PRESSURE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ECHOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; KOREAN (PEOPLE); MAJOR CLINICAL STUDY; MALE; MASS SCREENING; NONALCOHOLIC FATTY LIVER; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; MIDDLE AGED; REGRESSION ANALYSIS; SOUTH KOREA;

CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; REGRESSION ANALYSIS; REPUBLIC OF KOREA; RISK FACTORS;

EID: 84978946903     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2016.07.003     Document Type: Article

References (32)

1. [1] Tsimikas, S., Hall, J.L., Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J. Am. Coll. Cardiol. 60 (2012), 716–721.
2. [2] Dube, J.B., Boffa, M.B., Hegele, R.A., Koschinsky, M.L., Lipoprotein(a): more interesting than ever after 50 years. Curr. Opin. Lipidol. 23 (2012), 133–140.
3. [3] Dahlen, G.H., Lp(a) lipoprotein in cardiovascular disease. Atherosclerosis 108 (1994), 111–126.
4. [4] Berglund, L., Anuurad, E., Role of lipoprotein(a) in cardiovascular disease current and future perspectives. J. Am. Coll. Cardiol. 52 (2008), 132–134.
5. [5] Murase, T., Okubo, M., Amemiya-Kudo, M., Ebara, T., Mori, Y., Impact of elevated serum lipoprotein (a) concentrations on the risk of coronary heart disease in patients with type 2 diabetes mellitus. Metabolism 57 (2008), 791–795.
6. [6] Cantin, B., Despres, J.P., Lamarche, B., Moorjani, S., Lupien, P.J., Bogaty, P., et al. Association of fibrinogen and lipoprotein(a) as a coronary heart disease risk factor in men (the Quebec cardiovascular study). Am. J. Cardiol. 89 (2002), 662–666.
7. [7] Mora, S., Kamstrup, P.R., Rifai, N., Nordestgaard, B.G., Buring, J.E., Ridker, P.M., Lipoprotein(a) and risk of type 2 diabetes. Clin. Chem. 56 (2010), 1252–1260.
8. [8] Sung, K.C., Wild, S.H., Byrne, C.D., Lipoprotein (a), metabolic syndrome and coronary calcium score in a large occupational cohort. Nutr. Metab. Cardiovasc. Dis. 23 (2013), 1239–1246.
9. [9] Mansson, M., Kalies, I., Bergstrom, G., Schmidt, C., Legnehed, A., Hulten, L.M., et al. Lp(a) is not associated with diabetes but affects fibrinolysis and clot structure ex vivo. Sci. Rep., 4, 2014, 5318.
10. [10] Koschinsky, M.L., Marcovina, S.M., The relationship between lipoprotein(a) and the complications of diabetes mellitus. Acta Diabetol. 40 (2003), 65–76.
11. [11] Angulo, P., Lindor, K.D., Non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 17 (2002), S186–S190.
12. [12] Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50 (2001), 1844–1850.
13. [13] Lahsaee, S., Ghazizade, A., Yazdanpanah, M., Enhesari, A., Malekzadeh, R., Assessment of NAFLD cases and its correlation to BMI and metabolic syndrome in healthy blood donors in Kerman. Gastroenterol Hepatol Bed Bench 5 (2012), 183–189.
14. [14] Uchil, D., Pipalia, D., Chawla, M., Patel, R., Maniar, S., Narayani, et al. Non-alcoholic fatty liver disease (NAFLD) the hepatic component of metabolic syndrome. J Assoc Physicians India 57 (2009), 201–204.
15. [15] Nobili, V., Cianfarani, S., Agostoni, C., Programming, metabolic syndrome, and NAFLD: the challenge of transforming a vicious cycle into a virtuous cycle. J. Hepatol. 52 (2010), 788–790.
16. [16] Hamaguchi, M., Kojima, T., Takeda, N., Nagata, C., Takeda, J., Sarui, H., et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J. Gastroenterol. 13 (2007), 1579–1584.
17. [17] Tziomalos, K., Giampatzis, V., Bouziana, S.D., Spanou, M., Papadopoulou, M., Pavlidis, A., et al. Association between nonalcoholic fatty liver disease and acute ischemic stroke severity and outcome. World J. Hepatol. 5 (2013), 621–626.
18. [18] Choi, S.Y., Kim, D., Kim, H.J., Kang, J.H., Chung, S.J., Park, M.J., et al. The relation between non-alcoholic fatty liver disease and the risk of coronary heart disease in Koreans. Am. J. Gastroenterol. 104 (2009), 1953–1960.
19. [19] Yang, M.H., Son, H.J., Sung, J.D., Choi, Y.H., Koh, K.C., Yoo, B.C., et al. The relationship between apolipoprotein E polymorphism, lipoprotein (a) and fatty liver disease. Hepato-Gastroenterology 52 (2005), 1832–1835.
20. [20] Choe, Y.G., Jin, W., Cho, Y.K., Chung, W.G., Kim, H.J., Jeon, W.K., et al. Apolipoprotein B/AI ratio is independently associated with non-alcoholic fatty liver disease in nondiabetic subjects. J. Gastroenterol. Hepatol. 28 (2013), 678–683.
21. [21] Saadeh, S., Younossi, Z.M., Remer, E.M., Gramlich, T., Ong, J.P., Hurley, M., et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123 (2002), 745–750.
22. [22] Ortiz-Lopez, C., Lomonaco, R., Orsak, B., Finch, J., Chang, Z., Kochunov, V.G., et al. Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD). Diabetes Care 35 (2012), 873–878.
23. [23] Smits, M.M., Ioannou, G.N., Boyko, E.J., Utzschneider, K.M., Non-alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: results of a US national survey in three ethnic groups. J. Gastroenterol. Hepatol. 28 (2013), 664–670.
24. [24] Jenkins, A.J., Steele, J.S., Janus, E.D., Santamaria, J.D., Best, J.D., Plasma apolipoprotein (a) is increased in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 35 (1992), 1055–1059.
25. [25] Gruben, N., Shiri-Sverdlov, R., Koonen, D.P., Hofker, M.H., Nonalcoholic fatty liver disease: a main driver of insulin resistance or a dangerous liaison?. Biochim. Biophys. Acta 2014 (1842), 2329–2343.
26. [26] Birkenfeld, A.L., Shulman, G.I., Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology 59 (2014), 713–723.
27. [27] Bloomgarden, Z.T., Second world congress on the insulin resistance syndrome: insulin resistance syndrome and nonalcoholic fatty liver disease. Diabetes Care 28 (2005), 1518–1523.
28. [28] Utzschneider, K.M., Kahn, S.E., Review: the role of insulin resistance in nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab. 91 (2006), 4753–4761.
29. [29] Ding, L., Song, A., Dai, M., Xu, M., Sun, W., Xu, B., et al. Serum lipoprotein (a) concentrations are inversely associated with T2D, prediabetes, and insulin resistance in a middle-aged and elderly Chinese population. J. Lipid Res. 56 (2015), 920–926.
30. [30] Marzano, L., Colussi, G., Del Torre, M., Sechi, L.A., Catena, C., Relationships of plasma lipoprotein(a) levels with insulin resistance in hypertensive patients. Metabolism 63 (2014), 1439–1446.
31. [31] Rainwater, D.L., Haffner, S.M., Insulin and 2-hour glucose levels are inversely related to Lp(a) concentrations controlled for LPA genotype. Arterioscler. Thromb. Vasc. Biol. 18 (1998), 1335–1341.
32. [32] Neele, D.M., de Wit, E.C., Princen, H.M., Insulin suppresses apolipoprotein(a) synthesis by primary cultures of cynomolgus monkey hepatocytes. Diabetologia 42 (1999), 41–44.